Torrent Pharma Inc, a wholly owned subsidiary of India-based Torrent Pharmaceuticals Limited, announced on Thursday that it has commenced shipping the generic version of Xeris's Keveyis (dichlorphenamide), 50mg tablets in the United States.
This follows final approval from the US Food and Drug Administration (FDA) for it its Abbreviated New Drug Application. Torrent is distributing the product through specialty pharmacies beginning this month.
Dichlorphenamide tablets are indicated for the treatment of primary hyperkalemic periodic paralysis and related variants, a rare condition that causes sudden episodes that affect the muscles, resulting in extreme muscle weakness or temporary paralysis – most often the inability to move the muscles of the arms and legs.
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US
Aurisco announces Yangzhou, China manufacturing site's successful FDA inspection
Teva Pharmaceuticals and Alvotech expand biosimilars partnership in the US
Sandoz to invest USD90m in Biosimilar Technical Development Center in Slovenia